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Vascular NADH/NADPH Oxidase Is Involved in Enhanced
Superoxide Production in Spontaneously Hypertensive Rats
Guillermo Zalba, Francisco J. Beaumont, Gorka San Jose´, Ana Fortun˜o, Marı´a A. Fortun˜o,
Juan C. Etayo, Javier Dı´ez
Abstract—This study was designed to test the hypothesis that stimulation of nicotinamide adenine dinucleotide/
nicotinamide adenine dinucleotide phosphate (NADH/NADPH) oxidase is involved in increased vascular superoxide
anion (zO22) production in spontaneously hypertensive rats (SHR). The study was performed in 16-week-old and
30-week-old normotensive Wistar-Kyoto rats (WKY16 and WKY30, respectively) and in 16-week-old and 30-week-old
SHR (SHR16 and SHR30, respectively). In addition, 16-week-old SHR were treated with oral irbesartan (average dose
20 mg/kg per day) for 14 weeks (SHR30-I). Aortic NADH/NADPH oxidase activity was determined by use of
chemiluminescence with lucigenin. The expression of p22phox messenger RNA was assessed by competitive reverse
transcription–polymerase chain reaction. Vascular responses to acetylcholine were determined by isometric tension
studies. Aortic wall structure was studied, determining the media thickness and the cross-sectional area by morphometric
analysis. Whereas systolic blood pressure was significantly increased in the 2 groups of hypertensive animals compared
with their normotensive controls, no differences were observed in systolic blood pressure between SHR30 and SHR16.
No other differences in the parameters measured were found between WKY16 and SHR16. In SHR30 compared with
WKY30, we found significantly greater p22phox mRNA level, NADH/NADPH-driven zO22 production, media thickness,
and cross-sectional area and an impaired vasodilation in response to acetylcholine. Treated SHR had similar
NADH/NADPH oxidase activity and p22phox expression as the WKY30 group. The vascular functional and
morphological parameters were improved in SHR30-I. These findings suggest that an association exists between p22phox
gene overexpression and NADH/NADPH overactivity in the aortas of adult SHR. Enhanced NADH/NADPH
oxidase–dependent zO22 production may contribute to endothelial dysfunction and vascular hypertrophy in this genetic
model of hypertension. (Hypertension. 2000;35:1055-1061.)
Key Words: endothelium n rats, inbred SHR n superoxides n hypertrophy
An exaggerated production of superoxide anion ( zO22) bythe vascular wall has been observed in different animal
models of hypertension, including spontaneously hyperten-
sive rats (SHR).1–3 In the majority of cases, the source of
zO22 is uncertain, although involvement of endothelial nitric
oxide synthase4,5 and xanthine oxidase6,7 have been sug-
gested. A growing amount of evidence supports the possibil-
ity that increased oxidative inactivation of nitric oxide (NO)
by an excess of zO22 may account for the decrease in available
NO and endothelial dysfunction seen in SHR.8–10 On the
other hand, recent findings suggest that zO22 may participate
in vascular hypertrophy by stimulating the growth of vascular
smooth muscle cells (VSMCs).11,12
Several observations suggest that the nicotinamide adenine
dinucleotide/nicotinamide adenine dinucleotide phosphate
(NADH/NADPH) oxidase system accounts for the majority
of zO22 generation in the vessel wall.13,14 The vascular
NADH/NADPH oxidase appears to be structurally and func-
tionally different from the neutrophil oxidase. The endothelial
and VSMC NADH/NADPH oxidases are probably not all
similar. All components of the NADPH-oxidase enzyme have
been found in endothelial cells.15 In contrast, only p22phox
could be identified in VSMCs and has been shown to
participate in the increased zO22 production on stimulation
with angiotensin II.16
We have hypothesized that stimulation of NADH/NADPH
oxidase may contribute to increased vascular zO22 production
in SHR. Thus, the present study was designed to test whether
NADH/NADPH oxidase activity is enhanced and p22phox
gene expression is upregulated in the aortas of SHR. In
addition, we also investigated whether blockade of angioten-
sin II type 1 (AT1) receptors with irbesartan modifies the
enzyme in SHR.
Methods
Animals and Design
The investigation was performed according to the European Com-
munity guidelines for animal ethical care and use of laboratory
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animals (Directive 86/609). Experiments were performed with rats
provided by Harlan UK Limited (Blackthorn, Bicester, Oxon, UK).
The rats were housed in cages maintained in a humidity- and
temperature-controlled room and fed a standard diet. Sixteen-week-
old male SHR (n590) and their normotensive genetic controls,
Wistar-Kyoto rats (WKY) (n560), were studied in the following
manner: (1) 16-week-old WKY (n530) and SHR (n530) were killed
to perform studies in young rats (groups WKY16 and SHR16,
respectively); (2) 16-week-old WKY (n530) and SHR (n530) were
observed in our colony for additional 14 weeks and killed at 30
weeks of age to perform studies in adult rats (groups WKY30 and
SHR30, respectively), and (3) 16-week-old SHR (n530) were treated
with irbesartan and killed at 30 weeks. The drug was dissolved in
drinking water and the concentration was adjusted for the daily water
intake and body weight to obtain an average daily dose of 20 mg/kg
body wt. In each group of animals, 10 rats were used to measure
endothelial function in intact vessels and NADH/NADPH oxidase
activity in vessel homogenates, 10 rats were used to determine
vascular p22phox messenger RNA (mRNA) expression, and the
remaining 10 rats were used for aortic morphometric analysis.
Systolic blood pressure (SBP) was measured every 2 weeks by the
standard tail-cuff method. For measurement of isometric wall tension
and enzymatic and molecular studies, rats were killed by decapita-
tion. The thoracic aorta then was carefully excised and dissected,
adventitial tissues were carefully removed, and the vascular wall was
washed thoroughly with normal saline to remove any contaminating
blood.
Measurement of zO22 Production in
Aortic Homogenates
Vascular zO22 was estimated with lucigenin-enhanced chemilumi-
nescence.17 Aortic segments (2 to 3 cm) were placed in chilled
modified Krebs/HEPES buffer and homogenized on ice with a
glass/glass motor-driven tissue homogenizer for 2 minutes in
50 mmol/L PBS, which contained 0.01 mmol/L EDTA. In some
experiments the endothelium was removed by rubbing. The homog-
enate was centrifuged at 1000g for 10 minutes. The pellet was
discarded and the supernatant was stored on ice until use. Protein
content was measured by the method of Bradford.18 NADH or
NADPH oxidase activity was measured by chemiluminescence in a
scintillation vial containing HEPES buffer, 250 mmol/L lucigenin, in
2 mL buffer phosphate. The chemiluminescence, which occurred
over the ensuing 5 minutes in response to the addition of either
100 mmol/L NADH or 100 mmol/L NADPH, was recorded. No
activity could be measured in the absence of NADH or NADPH.
Reactions were initiated by the addition of 20 mL homogenate. To
determine the zO22 dependency of the lucigenin-enhanced chemilu-
minescence obtained from vascular homogenates, we examined the
effect of Cu21/Zn21 superoxide dismutase (SOD) (2000 U/mL) on
zO22 production after stimulation of homogenates with NADH. In
some experiments, membranes and cytosol were separated by cen-
trifugation (50 000g for 30 minutes). Twenty-five microliters of
either the supernatant or the particulate fraction were used to
examine NADH oxidase–dependent and NADPH oxidase–depen-
dent zO22 production of these subcellular fractions.
Endothelium-Dependent and
Endothelium-Independent Relaxations
After washing, each aorta was cut into 2- to 3-mm rings (6 per rat).
The rings were suspended in a vessel that contained 10 mL of
Krebs-Henseleit solution with the following composition (in
mmol/L): 118.4 NaCl, 4.74 KCl, 1.18 MgSO2, 0.7 H2O, 1.19
KH2PO4, 2.52 CaCl2, 0.2 H2O, 25 NaHCO3, and 11.5 glucose (pH,
7.34). The solution was oxygenated with a 95% O2–5% CO2 mixture
and maintained at 37°C in a thermostated bath. Two stainless steel
wires were inserted into the vascular lumen; one was anchored to a
stationary support and the other was connected to a force isometric
transducer. The rings were incubated for 60 minutes for equilibration
at a resting tension of 2g with buffer exchanges every 15 minutes
during this period. Changes in isometric forces were analyzed and
recorded by an Isolated Organs Data Acquisition Program (Proto5).
The rings were then maximally contracted with norepinephrine (1027
mol/L), and once a plateau had been reached, the endothelium-
dependent and endothelium-independent relaxations were studied by
plotting the concentration-response curves for the responses to 1029
to 1025 mol/L acetylcholine (Ach) and to 1029 to 1026 mol/L sodium
nitroprusside (SNP), respectively. Endothelium-dependent and en-
dothelium-independent relaxations were expressed as percentages of
decline of the contraction induced by norepinephrine. These values
were then plotted against the negative logarithm of the agonist dose
to produce dose-response curves. Dose-response curves were ana-
lyzed, and the EC50 value (the concentration for half-maximal
response) for relaxation of each ring was calculated by logistic
analysis and expressed as the pD2 defined as 2log (EC50).
Reverse Transcription–Polymerase Chain Reaction
for p22phox
Total RNA was extracted from homogenized thoracic aortas with the
use of Ultraspec RNA reagent. mRNA was isolated from total RNA
with the Oligotex mRNA kit (Qiagen), and mRNA concentration
was determined spectrometrically. The expression of p22phox was
quantified in the aorta by a competitive reverse transcription–
polymerase chain reaction (RT-PCR) method, as described by
Gilliland et al.19 On the basis of rat p22phox cDNA sequence,20 the
oligonucleotides 59-GCTCATCTGTCTGCTGGAGTA-39 and 59-
ACGACCTCATCTGTCACTGGA-39 were selected as sense and
antisense primers, respectively. The p22phox-specific primers am-
plified a 435-bp PCR product. The identity of this PCR product was
verified by sequencing. The heterologous DNA template (p22phox
competitor) was constructed with the use of a PCR-MIMIC construc-
tion kit (Clontech), following the manufacturer’s instructions. The
obtained 318-bp p22phox competitor contained the p22phox gene–
specific sequences incorporated at the ends. This 318-bp fragment
was cloned in a pGEMT vector (Promega), linearized by digestion
with Sca I, and subjected to in vitro transcription into RNA. The
purified p22phox-construct RNA was quantified spectrometrically.
Both RT and PCR were performed in a single tube with gene-
specific primers and specific target RNAs, with the use of the
Superscript 1-step RT-PCR System (Life Technologies). RT-PCR
was performed with constant amounts of aortic mRNA (35 ng)
together with a range of amounts between 106 and 105 molecules of
competitor RNA. RT-PCR reaction mixture (50 mL) contained aortic
and competitor RNA, a buffer containing 0.2 mmol/L of each dNTP,
and 1.2 mmol/L MgSO4, 20 pmol/L of primer, 20 U of Rnase
inhibitor (Pharmacia Biotech Inc), and 1 mL of a RT/Taq Mix
containing a mixture of Superscript II Reverse Transcriptase and Taq
DNA Polymerase. All components necessary for RT-PCR were
mixed in 1 tube, and RT (55°C for 30 minutes and then to 94°C for
2 minutes) was automatically followed by PCR cycling (35 cycles
with a temperature profile of 94°C for 20 seconds, 60°C for 25
seconds, and 72°C for 1 minute and finally 5 minutes at 72°C for
quantification of p22phox mRNA) without additional steps. The
PCR products were run on a 2% agarose gel, stained with ethidium
bromide, visualized by UV illumination, and photographed. The
amounts of target and competitor PCR product were quantified by
densitometric scanning of the film negative. To correct for differ-
ences in size of target (435 bp) and competitor (318 bp) p22phox
PCR products, the amounts of competitor PCR product were multi-
plied by 1.368 (435/318). The ratio of target to competitor PCR
product was plotted against the number of competitor construct
molecules on a log-log scale. At the point in which equal molar
amounts of target and competitor product were yielded by PCR (ie,
competition ratio51), the original number of transcript in the aortic
sample was defined by the known input of competitor construct
molecules.
Vascular Morphology
Before the animals were killed, they were weighted and anesthetized
(sodium thiopental, 30 mg/kg IP). Subsequently, the thoracic aorta
was fixed by retrograde perfusion as we have previously described.21
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In brief, the aorta was cannulated with a polyethylene catheter, the
heart was arrested in diastole by an intracarotid injection of KCl (1.0
mol/L, 1 mL), and the right atria were incised to allow drainage of
blood and perfusate. After initial perfusion with normal saline buffer
to wash the blood, 4% paraformaldehyde was perfused for 5 minutes
at a pressure equal to the mean arterial pressure determined before
the animals were killed. The thoracic aorta was excised and trans-
versally cut in 8 slices. The slices were alternatively separated into 2
groups, postfixed for 5 hours by immersion in buffered 4% parafor-
maldehyde and 10% formalin, respectively, and finally, dehydrated
and embedded in paraffin. Transversal sections (4 mm in thickness)
of the thoracic aorta were obtained from the 4 paraformaldehyde-
fixed, paraffin-embedded specimens. Media thickness (MT) and
cross-sectional area (CSA) were determined by morphometry with
an automated image analysis system (Visilog 4.1.5, Noesis) as
previously described by van Gorp et al.22 For this purpose, 1 section
of each specimen (4 from each rat) was stained for elastin fibers.
Sections were analyzed under the microscope (34), and images of
the whole aortic ring were digitized (final resolution of 85.5 mm2/
pixel). Stained elastic lamellae were segmented by interactive
gray-level thresholding, and after binary processing and analysis,
CSA and MT were obtained. CSA reflects the degree of arterial
hypertrophy better than MT because it is not influenced by the
variations in the perfusion pressure.23
A monoclonal mouse antibody against rat monocyte/macrophages
(ED1, Serotec)24 at a concentration of 1:100 in PBS was applied for
20 minutes. In control experiments, we checked that ED1 is specific
for rat monocyte macrophages and does not recognize granulocytes,
lymphocytes, endothelial cells, or smooth muscle cells. Fluorescein-
conjugated goat anti-mouse antibody (Dakopatts) was used as a
second antibody at a concentration of 1:40.
Statistical Analysis
Data are expressed as mean6SEM. Differences among the 5 groups
of rats were tested by a 1-way ANOVA. A Scheffe´’s post hoc test
was used to examine differences between groups when significance
was indicated. Probability values ,0.05 were considered significant.
Results
Blood Pressure
At the age of 16 weeks, SBP was higher (P,0.01) in SHR16
than in WKY16 (Table). Values of SBP remained higher in
SHR than in WKY along the experimental 14-week period.
Therefore, at the end of the 14-week-period of observation,
SBP was higher (P,0.01) in SHR30 than in WKY30 (Table).
No differences were found in SBP between SHR30 and SHR16.
SBP was lower (P,0.01) in SHR30-I than in SHR30 (Table).
Most rats (80%) in the SHR30-I group exhibited final values
of SBP above the upper normal limit measured in WKY30
(176 mm Hg).
p22phox mRNA Expression
In preliminary experiments, we proved that there were no
differences in the rate of transcription of the target and
competitor sequences. A representative competitive RT-PCR
experiment of aortic p22phox mRNA in young and adult rats
is shown in Figure 1a. In initial experiments, p22phox was
amplified from cDNA in the presence of several serial
dilutions of the p22phox competitor. The results of these
experiments enabled us to find the most appropriate amounts
of the p22phox competitor. Thus, definitive experiments were
performed with different amounts of p22phox competitor
comprised between 105 and 106 molecules. No differences in
the p22phox mRNA level were found between WKY16 and
SHR16 (36856813 versus 42186707 molecules of p22phox
mRNA/ng mRNA) (Figure 1b). In contrast, p22phox mRNA
level was 2.5-fold higher in SHR30 than in WKY30
(10 45561056 versus 42216349 molecules of p22phox
mRNA/ng mRNA, P,0.01) (Figure 1b). Furthermore, the
p22phox mRNA level was greater (P,0.01) in SHR30 than in
SHR16. After treatment with irbesartan, p22phox mRNA
expression was lower (P,0.01) in SHR30-I (3456 molecules
of p22phox mRNA/ng mRNA) than in SHR30, and the values
in treated SHR were similar to those measured in WKY30
(Figure 1b).
NADH/NADPH Oxidase Activity
No differences were found between WKY16 and SHR16 in
NADH oxidase activity (5.4560.66 versus 5.9660.77 nmol
zO22 z min21 z mg21) and NADPH oxidase activity (1.9260.16
versus 1.7360.27 nmol zO22 z min21 z mg21) (Figure 2). In
contrast, both activities were higher (P,0.01) in SHR30 than
in WKY30 (11.0160.81 versus 5.8160.74 nmol zO22 z min21 z
mg21 for NADH oxidase activity; 5.0960.41 versus
2.2160.19 nmol zO22 z min21 z mg21 for NADPH oxidase
activity). The activity of the oxidase was lower (P,0.01) in
SHR30-I than in SHR30 (5.5060.53 nmol zO22 z min21 z mg21
for NADH oxidase activity and 2.3160.27 nmol zO22 z min21 z
mg21 for NADPH oxidase activity) (Figure 2).
Blood Pressure and Parameters of Vascular Function and Morphology in Normotensive and Hypertensive
Rats
Parameter WKY16 SHR16 WKY30 SHR30 SHR30-I
SBP, mm Hg 16364 23465* 16463 23063* 18262
Endothelium-dependent relaxations
Maximum response to Ach, % 8067 6666 8065 3465† 7466
pD2 (to Ach) 6.4760.11 6.4460.18 6.3160.17 6.4160.13 6.5960.21
Endothelium-independent relaxations
pD2 (to SNP) 8.2660.06 8.3260.09 8.3860.08 8.0760.05‡ 7.9060.09‡
Media thickness, mm 0.17660.009 0.17760.006 0.19660.006 0.22660.008‡ 0.20760.010
Cross-sectional area, mm2 0.42360.023 0.44360.021 0.47760.019 0.63260.035‡ 0.57360.036
Values are expressed as mean6SEM of 10 rats.
*P,0.01 compared with WKY16, WKY30, and SHR30-I.
†P,0.05 compared with WKY16, SHR16, WKY30, and SHR30-I.
‡P,0.05 compared with WKY16, SHR16, and WKY30.
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To assess the cellular source of increased NADH/NADPH
oxidase activity in the vascular wall, some experiments were
performed in deendothelized preparations. Although removal
of the endothelium diminished slightly the NADH oxidase
activity in aortic homogenates from SHR30 (with endotheli-
um, 10.5760.17 nmol zO22 z min21 z mg21; without endothe-
lium, 8.6260.51 nmol zO22 z min21 z mg21), the difference was
not statistically significant.
To determine the zO22 dependency of the lucigenin-
enhanced chemiluminescence obtained from homogenates of
rat aorta, we examined the effect of native Cu21/Zn21 SOD.
As shown in Figure 3, SOD at very high concentrations (2000
U/mL) was effective in reducing the chemiluminescence
signal in response to stimulation with NADH.
NADH-dependent and NADPH-dependent oxidase activi-
ties in adult rats were located predominantly in the particulate
fraction (Figure 4). NADH-driven zO22 production measured
in the particulate fraction was higher (P,0.01) in SHR30 than
in WKY30 (159616 versus 5966 nmol z min21 z mg21).
NADPH-driven zO22 production measured in the particulate
fraction was also higher (P,0.01) in SHR30 than in WKY30
(4863.7 versus 11.962.1 nmol z min21 z mg21). Cytosolic
activity was minimal in all the animals tested (Figure 4).
High concentrations of lucigenin can produce a redox cycle
with flavin-containing enzymes, leading to artifactual in-
creases in estimates of zO22.25 This does not occur with low
concentrations of lucigenin (5 mmol/L).26 Experiments with
5 mmol/L lucigenin revealed that NADH oxidase activity was
greater (P,0.01) in aortas from SHR30 than in aortas from
WKY30 (9963 vs 5663 counts z min21 z mg21).
Vascular Relaxations
Whereas no differences in the maximal relaxations in re-
sponse to Ach were observed between WKY16 and SHR16,
this parameter was lower (P,0.05) in SHR30 than in WKY30
(Table). Furthermore, the response to Ach was lower
(P,0.05) in SHR30 than in SHR16 (Table). Irbesartan-treated
SHR exhibited a normal response to Ach (Table). There were
no significant differences in the sensitivity to Ach (pD2
values) among the different groups of animals (Table).
Maximum endothelium-independent relaxations to SNP
were reached at the same concentration (331026 mol/L) in
hypertensive and normotensive rats, irrespective of age and
treatment. There were no significant differences in the pD2
values between WKY16 and SHR16 (Table). Nevertheless, pD2
values were lower (P,0.05) in SHR30 and SHR30-I than in
WKY30 (Table).
Morphological Analysis
There were no differences in MT and CSA between WKY16
and SHR16 (Table). Otherwise, MT and CSA were greater
(P,0.05) in SHR30 than in WKY30 and SHR16 (Table).
Figure 1. Quantification of aortic
p22phox mRNA by competitive RT-PCR.
a, Representative experiment for mea-
surement of p22phox mRNA levels in
aortas of WKY16, SHR16, WKY30, SHR30,
and SHR30-I. As indicated at bottom of
gel, constant amount of mRNA was used
for competitive RT-PCR with different
amounts of p22phox-construct RNA mol-
ecules as competitor. b, p22phox mRNA
levels in aorta measured by competitive
RT-PCR in WKY16, SHR16, WKY30, SHR30,
and SHR30-I. Bars represent mean6SEM
of 10 animals in each group. *P,0.01
compared with WKY16, WKY30,, SHR16,
and SHR30-I.
Figure 2. NADH-driven (left) and NADPH-
driven (right) zO22 production in homoge-
nates from aortic tissue from WKY16,
SHR16, WKY30, SHR30, and SHR30-I. Bars
represent mean6SEM of 10 animals in
each group. *P,0.05 compared with
WKY16, SHR16, WKY30, and SHR30-I.
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Although the values of MT and CSA were lower in SHR30-I
than in SHR30, the difference was not significant (Table). No
differences were observed in these 2 parameters between
SHR30-I and WKY30 (Table).
In WKY and SHR, immunofluorescence did not reveal any
ED1-positive cells in the aorta. The absence of monocyte-
macrophages in SHR aorta was confirmed by light micros-
copy and morphological evaluation.
Discussion
The observations of the present study provide the first
indication that NADH/NADPH oxidase activity is increased
in the aortic wall of adult SHR and that this overactivity is
associated with upregulation of p22phox mRNA. In addition,
we found that overactivity of NADH/NADPH oxidase was
associated with impaired NO-dependent relaxation and media
hypertrophy in the aortas of adult SHR. Interestingly, the
enzyme abnormalities were not observed in the aortas of SHR
chronically treated with the AT1 receptor antagonist
irbesartan.
The NADH/NADPH oxidase is expressed in endothelial
cells,12 VSMCs,12,16,27 adventitial fibroblasts,14,28 and inflam-
matory neutrophils.29 Although we did not perform in situ
hybridization to determine which cell type(s) overexpress
p22phox mRNA, several findings support a role for VSMCs
as the potential source for oxidase overactivity found in adult
SHR. First, the examination of NADH/NADPH activity was
performed in aortas in which the adventitial tissue had been
previously removed. Second, deendothelialization did not
affect the level of NADH/NADPH oxidase activity. Third,
increased NADH/NADPH oxidase activity was associated
with hypertrophy of the media. Fourth, although it has been
reported that in the aortas of SHR exist an augmented
infiltration of monocyte-macrophage cells compared with the
aortas of WKY,30 we did not observe such an abnormality in
the aortas of adult SHR after microscopic examination.
Further, the preferred substrate for oxidases in macrophages
and neutrophils is NADPH rather than NADH.27
It is unclear which factors may be involved in upregulation
of p22phox mRNA expression present in the aortas of adult
SHR. It has been reported that hydralazine decreases both
blood pressure and NADPH oxidase activity in the aortas of
rats with experimentally induced hypertension.31 Thus, it is
possible that the increase in blood pressure is the stimulus
that induces p22phox mRNA expression in the aortas of adult
SHR. However, it has been shown that norepinephrine-
induced hypertension does not increase vascular NADH/
NADPH oxidase activity.17 The same authors have reported
that infusion of low amounts of angiotensin II that do not
increase blood pressure results in the increase in this oxidase
activity. Moreover, we found that p22phox mRNA expression
was normal in young SHR exhibiting the same degree of
elevation in blood pressure than did adult SHR. It therefore
appears that long-term exposure to arterial hypertension is
necessary to induce p22phox overexpression in SHR aorta.
Alternatively, other nonhemodynamic factors may be also
involved in this alteration (ie, tissue hormones and
cytokines).
One of these candidate factors is angiotensin II. As
previously mentioned, it has been found that p22phox mRNA
expression was elevated in rats receiving angiotensin II
infusion.31 This effect was inhibited by treatment with losar-
tan, suggesting that it was mediated by the interaction of
angiotensin II with AT1 receptors at the vascular wall. In
addition, angiotensin II has been found to stimulate p22phox
expression and zO22 production in VSMCs.16 Exaggerated
production of angiotensin II32 and enhanced expression of
both AT1 receptor and angiotensin-converting enzyme33 have
been reported in vessels of SHR compared with WKY.
Furthermore, an age-dependent increase of vascular angioten-
sin-converting enzyme activity in SHR has been shown.34
Altogether these data would suggest that high levels of
vascular angiotensin II can participate in p22phox overex-
pression in the aortas of adult SHR. This possibility is further
supported by our findings that both p22phox mRNA expres-
sion and NADH/NADPH oxidase activity are normalized in
irbesartan-treated SHR despite a noncomplete normalization
of blood pressure.
It has been suggested that the development of endothelial
dysfunction is linked to an exaggerated production of zO22 in
aortas from SHR.8 An enhanced production of zO22 may
result in inactivation of NO and generation of peroxynitrite.35
The resulting decrease in NO availability might be involved
in the impairment of NO-dependent relaxations.2,3,8–10 Thus,
oxidative degradation of NO caused by increased zO22 sec-
ondary to overactivity of NADH/NADPH oxidase likely
Figure 3. Effect of SOD on NADH-driven zO22 production in ho-
mogenates from aortic tissue from WKY30 and SHR30. Bars rep-
resent mean6SEM of 10 animals in each group. *P,0.05 com-
pared with control.
Figure 4. Subcellular localization of NADH oxidase and NADPH
oxidase activity in vascular homogenates from WKY30 and
SHR30. Bars represent mean6SEM of 10 animals in each group.
*P,0.01 compared with WKY30.
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explains the diminished response to Ach observed in the
aortas of adult SHR. This is further supported by the finding
that responses to Ach are normal in irbesartan-treated SHR,
which exhibit normal NADH/NADPH oxidase activity. Of
course, our results do not exclude a role for other potential
sources of zO22 (endothelial NO synthase, xanthine oxidase)
in the vascular wall of adult SHR. On the other hand, the
observation that responses to SNP are altered in both un-
treated and treated SHR suggests that other molecular alter-
ations (ie, diminished expression and activity of VSMC
guanylate cyclase)36,37 may also contribute to impaired vaso-
dilatory responsiveness in SHR.
On the other hand, it is possible that zO22 is also involved
in vascular hypertrophy. Recently, it has been shown that zO22
stimulates the proliferation of VSMCs.11 In addition, a role
for NADH/NADPH oxidase–derived zO22 and H2O2 has been
proposed in angiotensin II–induced VSMC growth.12 There-
fore, the association of NADH/NADPH oxidase overactivity
with medial hypertrophy in the aortas of adult SHR suggests
a contributing role for the enzyme in vascular wall remodel-
ing. The finding that the dimensions of the aortic wall were
not completely normalized in irbesartan-treated SHR sug-
gests that the maintenance of increased levels of blood
pressure after treatment may also account for the persistence
of a certain degree of aortic hypertrophy in these rats.
In summary, we reported that NADH/NADPH oxidase
activity is abnormally increased in the aortic wall of adult
SHR and that this abnormality is associated with upregulated
p22phox mRNA expression. Our findings suggest that long-
term exposure to hypertension, possibly combined with other
factors (ie, local overproduction of angiotensin II), may play
a role in p22phox upregulation and enzyme overactivity in the
media layer from the aortas of these rats. Enhanced NADH/
NADPH oxidase–mediated zO22 production might contribute
to functional and structural alterations present in the aortas of
adult SHR. Further experiments are necessary to elucidate the
precise mechanism through which chronic blockade of AT1
receptors prevents overstimulation of vascular NADH/
NADPH oxidase in this genetic model of hypertension. The
significance of these experimental results is underlined by
clinical data indicating the occurrence of increased zO22
production in humans with essential hypertension.38,39
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